Ozone as a complement therapy in the treatment of COVID-19

Autores

  • Jorge Bomfim Fróes de Farias Nucleus Reabilitação Cardí­aca
  • Antonio Pedro Fróes de Farias FACEMP
  • Anelize Gimenez de Souza FAN

DOI:

https://doi.org/10.33233/rbfe.v19i2.4116

Resumo

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called "coronavirus 2019" (COVID-19), has become a threat to the general population and health professionals worldwide [1]. The clinical features of COVID-19 is like that of other respiratory viruses, with specifically, fever, generally dry cough, tiredness and, in more severe cases, dyspnea, pulmonary bleeding, severe lymphopenia and renal failure [2].

For diagnosis, the World Health Organization (WHO) recommends the collection of samples from the upper or lower respiratory tract. In the laboratory, the amplification of the genetic material extracted from the saliva or mucus sample is carried out by means of a reverse transcription followed by a polymerase chain reaction (RT-PCR), which involves the synthesis of a double-stranded DNA molecule from of an RNA template, in the search for conserved parts of the coronavirus genetic code. In patients with a confirmed diagnosis, the laboratory test should be repeated to assess the release of viral particles, before leaving the isolation [3].

 The clinical manifestation and severity of the disease is directly related to the health condition of the infected individual. Symptoms are often mild as in a common cold or flu and it can progress to pneumonia. Ventilatory support therapy such as oxygen therapy and/or mechanical ventilation is necessary as an intervention method in the most severe cases of the disease [4]. Individuals with chronic respiratory diseases and other comorbidities can present the most severe form of COVID-19 and, for this reason, care with prevention should be emphasized [5]...

Biografia do Autor

Jorge Bomfim Fróes de Farias, Nucleus Reabilitação Cardí­aca

Nucleus Reabilitação Cardí­aca, Santo Antônio de Jesus, BA - Brasil

Antonio Pedro Fróes de Farias, FACEMP

Faculdade de Ciências e Empreendedorismo (FACEMP), Santo Antônio de Jesus, BA, Universidade Federal da Bahia (UFBA), Salvador, BA - Brasil

Anelize Gimenez de Souza, FAN

Faculdade Nobre (FAN), Feira de Santana, BA - Brasil

Referências

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):1-9. https://doi.org/10.1016/j.ijantimicag.2020.105924

Strabelli TMV, Uip DE. COVID-19 e o coração. Arq Bras Cardiol 2020. https://doi.org/10.36660/abc.20200209

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment coronavirus (COVID-19). 2020 Apr 06. [Actualization 2020 Apr 06; cited 2020 Apr 22]. http://www.ncbi.nlm.nih.gov/books/NBK554776/#article-52171.s8

Brasil. Diretrizes para diagnóstico e tratamento da COVID-19. Brasília: Ministério da Saúde; 2020. [Cited 2020 Abril 22]. https://portalarquivos.saude.gov.br/images/pdf/2020/April/13/Diretrizes-COVID-13-4.pdf

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J 2020. [ahead of print].

Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020;95:183-191. https://doi.org/10.1016/j.ijid.2020.03.013

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020 :105938 https://doi.org/10.1016/j.ijantimicag.2020.105938

Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W et al. Recent Progress in understanding 2019 novel coronavirus associated with human respiratory disease: detection, mechanism and treatment. Int J Antimicrob Agents 2020:105950. https://doi.org/10.1016/j.ijantimicag.2020.105950

Gordon CJ, Tchesnokov EP, Feng JY, Porter D.P, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavírus. J Biol Chem 2020;295915):4773-9. https://doi.org/10.1074/jbc.ac120.013056

Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci Biol Med 2011;2(1):66-70. https://doi.org/10.4103/0976-9668.82319

Sciorsci RL, Lillo E, Occhiogrosso L, Rizzo A. Ozone therapy in veterinary medicine: a review. Res Vet Sci 2020;130:240-6. https://doi.org/10.1016/j.rvsc.2020.03.026

Viebahn-Hänsler R. The use of ozone in medicine: mechanisms of action. Munich. 2003. [cited 2020 Abril 23]. http://www.altered-states.net/barry/update247/TheUseofOzoneinMedicine.pdf

Clavo B, Esparragón FR, Abreu DR, Sánchez GM, Llontop P, Bujanda DA et al. Modulation of oxidative stress by ozone therapy in the prevention and treatment of chemotherapy-induced toxicity: review and prospects. Antioxidants 2019;8(12):588. https://doi.org/10.3390/antiox8120588

Hudson JB, Sharma M, Vimalanathan S. Development of a practical method for using ozone gas as a virus decontaminating agent. Ozone Sci Eng 2009;31(3):216-23. https://doi.org/10.1080/01919510902747969

Madu IG, Belouzard S, Whittaker GR. SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. Virology 2009;393:265-71. https://doi.org/10.1016/j.virol.2009.07.038

Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C et al. Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19. Rev Esp Anestesiol Reanim 2020 Apr 14. [ahead of print]. https://doi.org/10.1016/j.redar.2020.03.004

ISCO3. Potential use of ozone in SARS-CoV-2/COVID-19. Madri; 2020 March 14. International Scientific Committee of Ozone Therapy ISCO3. [cited 2020 April 5]. Disponível em: http://www.isco3.org

Guangjian N, Hongzhi Y. Clinical study for ozonated autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19). Tianjin, 2020 Feb. 24. Tianjin University. [cited 2020 April 6]. http://www.chictr.org.cn/showproj.aspx?proj=49947

Huiling H, Tong X. A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19). Tianjin, 2020 Feb 23. Tianjin University. [Acesso em 2020 April 6]. http://www.chictr.org.cn/showprojen.aspx?proj=49747

Publicado

2020-05-10

Edição

Seção

Editorial